Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer answered questions about. When a caller mentioned that Cathie Wood invested in the stock, Cramer remarked, “That’s, it’s a ...
Abstract: This paper studies the estimation of dynamic route choice behavior of drivers with incomplete fixed location-based sensor data, such as radio frequency identification (RFID) data. Unlike ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Recursion Pharmaceuticals, Inc. is one of them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a ...
In his decades-long career in tech journalism, Dennis has written about nearly every type of hardware and software. He was a founding editor of Ziff Davis’ Computer Select in the 1990s, senior ...
Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...
Recent discussions on X about Recursion Pharmaceuticals (RXRX) have centered around the company's notable stock price surge of 14% over the past month, a performance that stands out against a ...
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.27, marking a +1.15% move from the previous day. The stock's performance was ahead of the S&P 500's daily gain of 0.83%. At ...
Some examples of narcissistic behavior include inflating one’s accomplishments to gain praise, ignoring other people’s feelings, and deliberately taking credit for someone else’s work. Narcissistic ...
Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...